Drug Trial Radar · NCT04782128
Evaluation of RC28-E Injection in Diabetic Retinopathy
Last checked: Nov 19, 2026Latest source record: Oct 11, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
120
Planned (sponsor's estimate)
Start
May 25, 2021
Primary completion
May 2024
Study completion Jul 2024
Sponsor
- Lead sponsor
- RemeGen Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 4, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, open-label, multicenter study of the efficacy and safety of RC28-E injection (a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF-2) in the treatment of patients with moderately severe to severe nonproliferative diabetic retinopathy.
Conditions
- Diabetic Retinopathy
Interventions
RC28-E injectionBiological
a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of subjects who have improved by ≥2 steps from baseline in DRSS score at week 24, 52Time frame: At Week 24, 52
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.